Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
pharmaceutical manufacturers in Europe:
Koninklijke DSM N.V.
sales of 8.11 billion Euros [US$9.63 billion]
of which 79%
(17.53 billion Euros [US$20.82 billion]
of which 43%
was Life Science), and
based in UNITED KINGDOM
(£20.59 billion [US$28.29 billion]
of which 41%
During the year ended December of 2020, sales at
Novo Nordisk As were 126.95 billion Danish Kroner (US$20.27 billion).
increase of 4.0%
versus 2019, when the company's sales were 122.02 billion Danish Kroner.
This was the third consecutive year of growth at Novo Nordisk As.
Sales of Diabetes and Obesity saw an increase
5.0% in 2020, from
102.84 billion Danish Kroner to 108.02 billion Danish Kroner.
Not all segments of Novo Nordisk As experienced an increase in sales in 2020:
sales of Biopharmaceuticals fell 1.3% to 18.93 billion Danish Kroner.